Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Tuspetinib for AML
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • Tuspetinib (HM43239) for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose Biosciences Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Research Initiative with Oregon Health & Science University

Sep 29, 2014 8:30am EDT

Aptose Biosciences to Present at Upcoming Investor Conferences

Sep 25, 2014 9:48am EDT

Aptose Biosciences Recruits Stephen B. Howell, M.D. to Act in the Capacity of Chief Medical Officer

Sep 08, 2014 7:00am EDT
RSS
  • Prev
    • 1...
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    © 2023 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap